Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells.
Although evidence is accumulating that type 2 cytokines play a part in the pathogenesis of bullous pemphigoid, little information is available concerning characterization of the cellular source of these cytokines involved in the pathogenesis of bullous pemphigoid. By using multiparameter flow cytometry, we investigated T cells capable of producing interleukin-2, -4, -10, and -13, interferon-gamma, and tumor necrosis factor-alpha and their correlated expression of skin-homing receptor (cutaneous lymphocyte-associated antigen) in peripheral blood and skin blister of patients with bullous pemphigoid. In peripheral blood of bullous pemphigoid patients, significantly increased frequencies of interleukin-4- and interleukin-13-producing cells were found as compared with those of healthy controls, and the majority of these type 2 cells was found in the cutaneous lymphocyte-associated antigen-positive population. The frequency of interferon-gamma-producing cells was also increased as compared with healthy subjects; however, the majority of this subset was found in the cutaneous lymphocyte-associated antigen-negative population. In the skin blister, the frequencies of interleukin-13- and interleukin-4-producing cells were much higher than those in the peripheral blood of bullous pemphigoid, whereas that of interferon-gamma producing cells was significantly lower. Furthermore, in bullous pemphigoid patients after therapy with systemic corticosteroids, the frequency of cutaneous lymphocyte-associated antigen-positive, but not cutaneous lymphocyte-associated antigen-negative, interleukin-13-producing cells was significantly decreased accompanied by an increased frequency of interleukin-10-producing cells, which was associated with clinical improvement. Thus, our results suggest that bullous pemphigoid is a unique organ-specific autoimmune disease characterized by an expansion of skin-homing interleukin-13-producing cells. In addition, corticosteroids may control such type 2 biased inflammatory responses in bullous pemphigoid by promoting the expansion of interleukin-10-producing cells.
Teraki
Y
Y
Department of Dermatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan. teraki@kyorin-u.ac.jp
Hotta
T
T
Shiohara
T
T
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D001768:Blister / Q000378:metabolism; D001773:Blood Cells / Q000378:metabolism; D001826:Body Fluids / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis; D018793:Interleukin-13 / Q000097:blood*; D015847:Interleukin-4 / Q000096:biosynthesis*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D010391:Pemphigoid, Bullous / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016201:Receptors, Lymphocyte Homing / Q000378:metabolism*; D012016:Reference Values; D012074:Remission Induction; D012867:Skin / Q000378:metabolism* / Q000473:pathology; D013601:T-Lymphocytes / Q000378:metabolism*
D000305:Adrenal Cortex Hormones; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; C063419:CTAGE1 protein, human; D018793:Interleukin-13; D008562:Membrane Glycoproteins; D016201:Receptors, Lymphocyte Homing; D016753:Interleukin-10; D015847:Interleukin-4